Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been assigned a consensus rating of “Moderate Buy” from the twenty-four brokerages that are presently covering the firm, Marketbeat.com reports. Ten research analysts have rated the stock with a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $800.3636.

REGN has been the topic of a number of analyst reports. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a report on Tuesday, July 7th. Finally, Canaccord Genuity Group dropped their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th.

Regeneron Pharmaceuticals Stock Down 0.3%

Shares of REGN opened at $807.65 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average price of $749.60 and a two-hundred day moving average price of $720.06. The stock has a market cap of $83.16 billion, a price-to-earnings ratio of 19.96, a P/E/G ratio of 1.59 and a beta of 0.20. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period in the prior year, the company posted $12.81 EPS. The company’s revenue was up 16.7% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,131 shares of the business’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the transaction, the executive vice president owned 12,003 shares of the company’s stock, valued at approximately $10,291,252.17. The trade was a 8.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 4,146 shares of company stock valued at $3,432,488. Company insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System lifted its position in shares of Regeneron Pharmaceuticals by 63,274.2% during the second quarter. California State Teachers Retirement System now owns 97,723,683 shares of the biopharmaceutical company’s stock worth $60,934,625,000 after purchasing an additional 97,569,482 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. Norges Bank bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $1,012,296,000. Price T Rowe Associates Inc. MD lifted its holdings in Regeneron Pharmaceuticals by 142.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after buying an additional 1,144,887 shares in the last quarter. Finally, Nuveen LLC boosted its position in Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after buying an additional 835,240 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron’s presentation at the Wells Fargo Healthcare Conference may provide investors with additional detail on its pipeline, commercial portfolio and strategy. However, the available report is a transcript and does not identify a new market-moving announcement. Wells Fargo conference transcript
• Neutral Sentiment: Recent fund commentary is mixed: Harbor Funds discussed the stock’s bullish potential, while American Century Investments reported selling its Regeneron position. These manager opinions may influence sentiment but do not change the company’s fundamentals. Harbor Funds commentary American Century fund sale
• Negative Sentiment: Several firms reiterated that investors who purchased REGN between August 1, 2025 and May 15, 2026 may seek lead-plaintiff status by September 14, 2026. The allegations focus on whether Regeneron adequately disclosed the protocol and risks of the Phase 3 fianlimab-Libtayo melanoma study, which ultimately failed; notices cite an earlier decline of roughly $102 per share from the class-period high. The repeated announcements increase litigation visibility and could keep a risk discount on the shares. Hagens Berman class-action notice Robbins Geller deadline notice
• Negative Sentiment: Analyst commentary also highlighted reasons to avoid REGN, including recent underperformance versus the broader market, adding to the cautious tone around the shares. Reasons to avoid REGN

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.